# Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma

> **NCT04189952** · PHASE2 · TERMINATED · sponsor: **University of Miami** · enrollment: 2 (actual)

## Conditions studied

- Diffuse Large B Cell Lymphoma
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Leukemia
- Marginal Zone Lymphoma

## Interventions

- **DRUG:** Acalabrutinib
- **DRUG:** Rituximab
- **DRUG:** Ifosfamide
- **DRUG:** Carboplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT04189952
- **Lead sponsor:** University of Miami
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-09-22
- **Primary completion:** 2021-06-30
- **Final completion:** 2022-03-01
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Investigator Decision
- **Last updated:** 2025-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04189952

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04189952, "Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04189952. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*